Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Barba

Showing results (101-110 of 103) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 103 results.
Bone Marrow Transplantation|October 28, 2014
Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over timeR Parody, R Martino, R de la Cámara, et al.
Journal of Hematology & Oncology|July 26, 2018
Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemiaE Genescà, A Lazarenkov, M Morgades, et al.
Immuno-Oncology Technology|February 6, 2025
Preclinical data and design of a phase I clinical trial of neoantigen-reactive TILs for advanced epithelial or ICB-resistant solid cancersJ Palomero, V Galvao, I Creus, et al.
Pageof 11

Showing results (101-110 of 103) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 103 results.
Bone Marrow Transplantation|October 28, 2014
Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over timeR Parody, R Martino, R de la Cámara, et al.
Journal of Hematology & Oncology|July 26, 2018
Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemiaE Genescà, A Lazarenkov, M Morgades, et al.
Immuno-Oncology Technology|February 6, 2025
Preclinical data and design of a phase I clinical trial of neoantigen-reactive TILs for advanced epithelial or ICB-resistant solid cancersJ Palomero, V Galvao, I Creus, et al.
Pageof 11